BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that its oral therapy pomalidomide was evaluated as a potential treatment for patients with relapsed and refractory multiple myeloma who have received prior therapy that includes REVLIMID (lenalidomide) and bortezomib. The clinical data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
